The Arthex biotech team

Our team

Dr. Beatriz Llamusí. CEO, Co-founder

Dr. Beatriz LlamusíMsC in Biochemistry and PhD for the University Miguel Hernández. 11 years of experience in rare neuromuscular diseases, produced 18 scientific articles and 5 related patents and has been PI in 5 competitive projects.

Dr. Rubén Artero. Advisor and Co-founder

Dr. Rubén ArteroMsc and PhD in Biochemistry, full professor of Genetics at the University of Valencia. Leader of the translational genomics lab in the UV. His laboratory is focused on the molecular basis of muscle atrophy in myotonic dystrophy and in identifying appropriate therapeutic targets and candidate drugs using cell, animal and bioinformatics approaches. During his doctoral degree, he discovered the muscleblind gene, the founding member of the MBNL family of proteins, he received six years of postdoctoral training at the Memorial Sloan-Kettering Cancer Center in New York studying Drosophila myogenesis.

Dr. Pedro Fernández. Director of Operations

Dr. Pedro FernándezMsc in Biochemistry, PhD for the Polytechnic University of Valencia and accredited RTTP by ATTP. 6 years of experience in technology transfer, project management and R&D management.

Description of the advisory board members:

Dr. Ramón Eritja. Institute of Advance Chemistry of Catalonia

Dr. Ramón Eritja

Director of the Nucleic Acids Chemistry Group at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC). He was a group leader and director of DNA synthesis facilities at the European Molecular Biology Laboratory (EMBL), Heidelberg (Germany) 1994-1999. He is a CSIC research professor in Barcelona from 2000 to the present. From 2012 to 2017 he was Director of IQAC-CSIC. He has remarkable contacts with several companies dedicated to RNA and DNA synthesis and works as advisor for companies developing therapeutic oligonucleotides.


Dr. Nicholas Johnson. Virginia Commonwealth University.

Dr. Nicholas JohnsonNicholas E. Johnson, MD, MSCI, FAAN is an associate professor of Neurology and Human and Molecular Genetics and vice chair of research in Neurology at Virginia Commonwealth University with a focus in inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester.

His laboratory is focused on identifying the pathogenesis of limb girdle muscular dystrophy, myotonic dystrophy, andfacioscapulohumeral muscular dystrophy and identifying appropriate clinical endpoints for these conditions. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders.

Dr. Eric Marcusson

Eric Marcusson, Ph. D. is a scientific director with extensive experience in preclinical drug discovery in the field of RNA therapeutics. Throughout his career he has worked with innovative technologies to identify genes that make effective targets for specific molecularly-targeted therapies and helped to drive these therapies into the clinic. He has played major roles in starting new therapeutic companies and has a passion for evaluating novel technologies that may lead to more efficient drug discovery platforms and effective treatments for patients in need.

Dr. Marcusson has his own consultancy firm to provide expert advice to start-ups, pharma industry and venture capitalists. He is also co-founder and CSO of Providence Therapeutics, specialized in mRNA vaccines. Previously, he played the role of scientific director at leading companies in the RNA therapeutics field, such as Regulus Therapeutics and Ionis Pharmaceuticals. In addition to his experience bringing novel RNA drugs to the clinic, he has been involved in business development that led to multiple alliances with large pharmaceutical companies and medical centers for drug discovery and development.


France Biotechnology

Invivo Capital

Innvierte CDTI